In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Elixir gets North American rights to Kissei's diabetes drug
18 Jul 2006
Japanese pharma Kissei licensed Elixir (genetics-based research of age-related, metabolic diseases) exclusive development and marketing rights to its Type II diabetes drug Glufast (mitiglinide calcium hydrate; formerly KAD1229) in the US, Canada, and Latin America. Elixir also gets rights to any Glufast combination products that are developed.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?